hotspot -WSS

hotspot

author：leisure time 2025-09-28 00:53:51 - browse：817

Garry Tan, CEO of Y Combinator Seb Daly/Web Summi

WASHINGTON — In San Francisco, Y Combinator’s firebrand chief executive Garry Tan is one of the startup economy’s most recognizable figures. Well before he became the leader of the coveted startup accelerator that bred global brands like Airbnb, Stripe and OpenAI, Tan was a self-made founder who sold his own company to Twitter.

But here in the nation’s political capital, Tan is far less known. He’s hoping to grow his influence here, offering up his vast network of founders as a source of expertise for regulators struggling to wrap their heads around new technologies like artificial intelligence and how best to rein it in.

“We’re happy to be a phone-a-friend for people who are trying to understand tech,” he told the Economic Club of Washington recently when asked how he’d measure success during Y Combinator’s first-ever policy-focused visit. “‘Little tech’ represents competition, and consumer choice,” he said later at a separate event in a dimly lit Senate room filled with a few dozen Congressional staffers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

WSS

Mystery swirls around US soldier who entered North Korea days ago, officials say

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

With measles on the rise, a personal story of a devastating disease

When a patient nears the end, a feared therapy can comfort

Venture capitalist Bob Kocher on the state of digital health

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Affirmative action in medical school literally saved lives

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Trump demands the U.S. pay no more for drugs than other countries … again

Military medical care influenced by rank and race, new study finds

How to save PrEP access — and even expand it

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Dementia risk linked to living in disadvantaged areas: Study

explore

HIV vaccine remains elusive. Immunologists keep trying new ideas

Hormonal contraceptives don’t actually treat endometriosis

When a patient nears the end, a feared therapy can comfort

US jobless claims fall again as labor market continues to flash strength

The stock market has soared this year, but will it last? Experts weigh in

NVIDIA and Google execs on the future of AI and drug discovery

hotspot

hotspot

hotspot

hotspot